NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Novartis Vaccines and Diagnostics 

475 Green Oaks Parkway

Holly Springs  North Carolina  Holly Springs  U.S.A.
Phone: 919-577-5000 Fax: 919-577-5197


SEARCH JOBS

Novartis Vaccines and Diagnostics is a division of Novartis focused on the development of preventive treatments. The division has two businesses: Novartis Vaccines and Chiron. Novartis Vaccines is the world's fifth-largest vaccines manufacturer and second-largest supplier of flu vaccines in the United States.

Novartis Vaccines is leading new innovation in vaccines research and manufacturing to protect health in areas of unmet medical need. Novartis is investing to build the first cell culture-derived influenza vaccine manufacturing facility in the US. Cell culture-derived influenza vaccine production represents the first major advancement in flu vaccine manufacturing in 50 years. Its advantages include greater speed, reliability, and flexibility in the vaccine manufacturing process.

Opportunities in Holly Springs, NC

To ensure an ample supply of safe and effective influenza vaccines, Novartis Vaccines is currently building a new manufacturing facilty in Holly Springs, North Carolina. The 400,000-square-foot manufacturing plant will be situated on a 167 acre site and is scheduled for completion in 2010. The Novartis Holly Springs facility is expected to produce up to 50 million seasonal doses of trivalent vaccines, and at least 150 million monovalent doses of vaccine in the event of a pandemic.

Novartis Vaccines has a range of opportunities in Holly Springs — from entry-level personnel to technicians, supervisors, and managers. Those who pursue their careers at the Holly Springs facility will be instrumental in meeting growing patient demand for seasonal influenza vaccines and in helping governments prepare for a possible flu pandemic.

Advancing Careers at Novartis

Novartis believes that its own success is directly tied to the success of its employees. Therefore, the company strives to be the best in business performance, scientific achievement and the quality of its workplace. Novartis is proud to have been recently named the most admired pharmaceutical company in the world by Fortune. The company is also ranked among the top employers by magazines such as Science, Working Mother, Diversity, and The Scientist.

Last Updated: 03-27-2008

 Key Statistics


Email:
Ownership:
Web Site: Novartis Vaccines and Diagnostics
Employees:
Symbol: 
 




Segment
Vaccines





 Company News
Novartis Vaccines and Diagnostics Begins Shipment of Fluvirin(R) Seasonal Influenza Vaccine for the U.S. Market Ahead of Schedule 8/5/2009 11:06:29 AM    More...
Flu Vaccine Makers To Set New Doses Record For Next Season, CSL Biotherapies, Sanofi Pasteur (SASY.PA), Novartis Vaccines and Diagnostics, GlaxoSmithKline (GSK), and MedImmune Vaccines 5/12/2008 2:48:46 PM    More...
ESBATech Starts Drug Discovery Collaboration With Novartis (NVS) 10/19/2005 5:13:10 PM    More...
Novartis (NVS) Breaks Ground On New Production Facility In Singapore 10/19/2005 5:12:56 PM    More...
Novartis Oncology (NVS) Release: First Results Of Major Study Show That Femara(R) Provides A Disease Free Survival Advantage VS. Tamoxifen In Adjuvant Treatment Of Early Breast Cancer 10/19/2005 5:12:33 PM    More...
Axentis Enterprise Helps Novartis (NVS) Gain Sarbanes-Oxley Section 404 Compliance One Year Ahead Of Deadline 10/19/2005 5:12:33 PM    More...
Inpharmatica Announces Chematica(TM) Agreement With Novartis (NVS) 10/19/2005 5:12:26 PM    More...
Novartis (NVS): New Study Finds Coartem (Artemether-Lumefantrine) Is The Most Effective Malaria Treatment In Areas Of High Resistance To Conventional Anti-Malarials 10/19/2005 5:10:53 PM    More...
Novartis (NVS) Files Exjade(R) New Drug Applications For Treatment Of Chronic Iron Overload Due To Blood Transfusions 10/19/2005 5:10:38 PM    More...